MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Clinical Cancer Research
03 Jun, 2020 ,

Ibiayi Dagogo-Jack conducted a study to evaluate ALK inhibitor sensitivity in cell lines with MET alterations and assessed antitumor activity of ALK/MET blockade in ALK-positive cell lines and 2 patients with MET-driven resistance. The researchers concluded that treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance.